
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Oncol. , 10 September 2020
Sec. Pharmacology of Anti-Cancer Drugs
Volume 10 - 2020 | https://doi.org/10.3389/fonc.2020.01756
This article is part of the Research Topic Natural Products as a Tool to Design New anti-MDR Lead Molecules View all 12 articles
A retraction of this article was approved in:
Retraction: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Squamous Cell Carcinoma by Down-Regulating NF-kB/COX-2/VEGF Pathway
RETRACTED: Corrigendum: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway
Citation: Liao X, Gao Y, Liu J, Tao L, Xie J, Gu Y, Liu T, Wang D, Xie D and Mo S (2020) Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway. Front. Oncol. 10:1756. doi: 10.3389/fonc.2020.01756
Received: 06 February 2020; Accepted: 05 August 2020;
Published: 10 September 2020; Retracted: 29 June 2021.
Edited by:
Francisco Estévez, University of Las Palmas de Gran Canaria, SpainReviewed by:
Diwakar Bastihalli Tukaramrao, University of Toledo, United StatesDisclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.